Trevena announces the publication of the health economic model OLINVYK® in the Journal of Comparative Effectiveness Research



Models demonstrate substantial overall savings for hospitals when using OLINVYK over IV morphine in postoperative care

CHESTERBROOK, Pa., July 12, 2021 (GLOBE NEWSWIRE) – Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel drugs for patients with central nervous system (CNS) disorders, today announced the release of the health business model for injection of OLINVYK (oliceridin ) in Journal of Comparative Effectiveness Research. The model estimates the budgetary impact of OLINVYK compared to IV morphine when used on demand in a hospital setting for postoperative pain.

The publication is titled “Cost-Effectiveness and Cost-Benefit Analysis of Oliceridine in the Treatment of Acute Pain”, with lead author Kit N. Simpson, DrPH, Professor of Leadership and Health Care Management, College Health Professions and Public Health, and Director, Comparative Effectiveness Data Analysis Resource (CEDAR) Core at the Medical University of South Carolina (DOI: ).

“I am delighted that the healthcare business model is now in the published literature – an important step that will continue to support the form review process for OLINVYK,” said Mark A. Demitrack, MD, senior vice president and medical director of Trevena. “We have had multiple opportunities to present these compelling cost compensation results to the medical community, and the response from hospital decision makers has always been positive and very encouraging. “

As previously announced, the model calculates a significant decrease in the total cost of care per 1,000 patients associated with OLINVYK, compared to IV morphine. These cost savings are due to potentially reduced adverse reactions (AEs) for patients treated with OLINVYK, as observed in the pivotal Phase 3 trials, and using cost estimates of AEs based on government sources and of the published literature.

The publication can be viewed at Although the cost savings in these economic models of health cannot be guaranteed, they are based on a generally accepted methodology, and pharmacy and therapeutics committees generally consider economic models of health when making decisions about pharmaceutical forms.

About the injection of OLINVYK® (oliceridin)
OLINVYK is a new chemical entity approved by the FDA in August 2020. OLINVYK contains archeridin, a schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an opioid analgesic intravenously and for which alternative treatments are insufficient. OLINVYK is available in 1 mg / 1 ml and 2 mg / 2 ml single dose vials and 30 mg / 30 ml single use vial for patient-controlled analgesia (PCA). The approved PCA doses are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please review important safety information, including the BOXED WARNING, and full prescribing information at

About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative drugs for patients with CNS disorders. The Company has a product approved in the United States, OLINVYK® (oliceridin) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for which alternative treatments are inadequate. The company’s new pipeline is based on Nobel Prize-winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for the maintenance treatment of opioid use disorders , TRV045 for diabetic neuropathic pain and epilepsy, and TRV027 for acute respiratory distress. syndrome and abnormal blood clotting in COVID-19 patients.

For more information, please visit

Forward-looking statements
Any statement contained in this press release regarding the Company’s future expectations, plans and prospects, including statements regarding the Company’s strategy, future operations, clinical development and testing of its therapeutic candidates, plans potential future product candidates, the marketing of approved drug products and other statements containing the words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may” , “Could”, “,”, “,” target “,” potential “,” will “,” would “,” could “,” should “,” continue “,” in progress “, or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. n due to various important factors, including: the marketing of any approved drug product, the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the applicants- the Company’s investigational drugs; uncertainties inherent in the conduct of clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of discussions with the FDA or other regulatory bodies regarding all or any part of its programs; uncertainties related to the marketing of OLINVYK; funding available; uncertainties relating to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other issues that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other documents filed by the company with the SEC from time to time. Further, the forward-looking statements included in this press release represent the views of the Company only as of the date hereof. The Company expects that subsequent events and developments may change the views of the Company. However, although the Company may choose to update these forward-looking statements at some time in the future, it specifically disclaims any obligation to do so, except as required by law.

For more information please contact:

Investor contact:

Dan Ferry
General manager
LifeSci Advisors, LLC
[email protected]
(617) 430-7576

PR and media contact:

Sasha bennett
Clyde Group
[email protected]
(239) 248-3409



Leave A Reply